Advisory Services Network’s Recursion Pharmaceuticals RXRX Stock Holding History

Advisory Services Network’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,461	Closed	-$29K	–	4158
2026 Q1	$29K	Sell	9,461 -1,050	-10%	-$4.06K	﹤0.01%	2964
2025 Q4	$43K	Buy	10,511 +1,170	+13%	+$5.79K	﹤0.01%	1781
2025 Q3	$45.6K	Sell	9,341 -1,064	-10%	-$5.59K	﹤0.01%	2515
2025 Q2	$61.9K	Sell	10,405 -389	-4%	-$1.91K	﹤0.01%	1719
2025 Q1	$57.1K	Sell	10,794 -153	-1%	-$1.11K	﹤0.01%	1588
2024 Q4	$74K	Buy	+10,947	New	+$73.6K	﹤0.01%	1540
2024 Q1	–	Sell	-1,110	Closed	-$10.9K	–	3243
2023 Q4	$10.9K	Buy	+1,110	New	+$7.92K	﹤0.01%	2821
2023 Q2	–	Sell	-300	Closed	-$2K	–	3238
2023 Q1	$2K	Hold	300	–	–	﹤0.01%	3431
2022 Q4	$2.31K	Buy	+300	New	+$2.94K	﹤0.01%	3393

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Advisory Services Network's RXRX Position: Q2 2026 in Review

Advisory Services Network sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 9,461 shares — an estimated $29K sold.

Advisory Services Network first reported a position in RXRX in Q4 2022 and held it in 9 quarters. The position peaked at $74K in Q4 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Advisory Services Network reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Advisory Services Network sold 9,461 Recursion Pharmaceuticals shares in Q2 2026, an estimated $29K.
Advisory Services Network first reported a position in Recursion Pharmaceuticals in Q4 2022 and held it in 9 quarters.
Advisory Services Network's Recursion Pharmaceuticals position peaked at $74K in Q4 2024.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.